This article is for educational and informational purposes only. It does not constitute medical advice. Always consult your GP or a registered healthcare provider before starting, stopping, or changing any medication.
Ozempic has become the most searched weight loss medication in Australia — and with tens of thousands of Australians searching for answers every month, the demand for reliable, up-to-date information has never been greater. Whether you have type 2 diabetes and want to understand your PBS entitlements, or you are hoping to access Ozempic for weight loss and need to know the real out-of-pocket cost, this guide covers everything that matters in 2026: what Ozempic actually is, how much it costs with and without PBS subsidy, who qualifies, what happened during the supply crisis, how it compares to Wegovy, what the clinical trials show, and what the risks are.
Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Danish pharmaceutical company Novo Nordisk. Originally engineered as a treatment for type 2 diabetes mellitus, it has since become the centrepiece of a global transformation in obesity medicine — one of the most clinically significant shifts in the treatment of chronic disease in decades.
Semaglutide works by mimicking GLP-1, a naturally occurring gut hormone released after eating. For a detailed breakdown of the receptor biology behind this mechanism, see how GLP-1 agonists work. It activates GLP-1 receptors across several organ systems simultaneously:
Ozempic is administered as a once-weekly subcutaneous injection via a pre-filled pen device. The approved doses for type 2 diabetes are 0.25 mg (titration only, not therapeutic), 0.5 mg, 1 mg, and 2 mg weekly, with dose escalation guided by tolerability and clinical response.
For researchers investigating GLP-1 receptor agonism at the molecular level — including binding kinetics, receptor selectivity, and downstream signalling cascades — access to validated research compounds is essential. Resources for semaglutide research peptides supporting GLP-1 mechanism studies in preclinical and laboratory contexts are available for researchers in this field.
This is the single most important fact for Australians to understand about Ozempic: the Pharmaceutical Benefits Scheme (PBS) lists Ozempic exclusively for the treatment of type 2 diabetes mellitus. As of 2026, it is not PBS-subsidised for weight loss, obesity, or any other indication.
That means the PBS subsidy and the private prescription market operate as two completely separate pathways — and the distinction has enormous implications for cost.
For Australians with a confirmed type 2 diabetes diagnosis who meet the prescribing criteria, Ozempic on the PBS costs approximately:
| Patient type | Approximate monthly cost |
|---|---|
| General patient | ~$42.50 per prescription |
| Concession card holder | ~$7.70 per prescription |
These are among the most affordable monthly costs for any GLP-1 therapy available globally. The concession price in particular represents extraordinary value for a medication that, without PBS subsidy, costs upwards of $150 per month at private rates.
PBS eligibility for Ozempic under the type 2 diabetes indication typically requires:
Your GP can initiate a PBS prescription without a specialist referral in most cases, though some clinical pathways or health funds may route complex cases through an endocrinologist or diabetes specialist.
For Australians seeking Ozempic without a type 2 diabetes diagnosis — that is, purely for weight management — the medication must be obtained via a private prescription at full cost. As of early 2026:
| Dose | Approximate monthly cost |
|---|---|
| 0.5 mg or 1 mg | ~$120–$170 per month |
| 2 mg (maintenance) | ~$200–$250 per month |
Annual cost on a private prescription ranges from approximately $1,440 to $3,000 per year depending on dose and pharmacy. These figures can vary between dispensing locations and may shift further as supply continues to normalise. Some telehealth platforms bundle consultation fees with ongoing prescription management, which affects the total effective monthly cost.
The Ozempic supply shortage was one of the most disruptive pharmaceutical supply events Australia had experienced in years. Beginning in 2022 and intensifying through 2023, global demand for semaglutide — driven largely by off-label weight loss prescribing, accelerated by social media coverage and celebrity endorsements — overwhelmed Novo Nordisk's manufacturing capacity.
Australia, as a relatively small market, bore a disproportionate share of the consequences. The TGA declared Ozempic an Actual Shortage at multiple points during 2023. Pharmacies received only partial stock allocations. Patients with type 2 diabetes who had been stable on Ozempic for years faced forced treatment interruptions and urgent medication switches. Waitlists at compounding pharmacies lengthened rapidly as patients and clinicians sought alternatives — though the TGA later issued warnings about the risks associated with compounded semaglutide products (addressed below).
In response to the shortage, the TGA introduced prescribing guidance in 2023 directing that Ozempic be prioritised for its approved T2DM indication, with off-label weight loss prescribing deprioritised during the period of constrained supply.
As of early 2026, the acute supply crisis has substantially resolved. Novo Nordisk has significantly expanded manufacturing capacity across its global facilities, and Australian pharmaceutical wholesalers report more consistent and predictable allocation of Ozempic stock. The TGA's active shortage declaration has been lifted.
Most metropolitan pharmacies in Sydney, Melbourne, Brisbane, Perth, and Adelaide carry reliable stock of the 0.5 mg and 1 mg pen devices. Regional and rural pharmacies may still experience intermittent gaps, and the 2 mg dose can be harder to source at smaller dispensing locations. If you are starting Ozempic or transferring pharmacies, a courtesy call ahead to confirm current stock is still worthwhile.
The PBS restriction to the T2DM indication remains in place regardless of supply conditions — this is a funding and regulatory decision, not a supply response, and it is unlikely to change for Ozempic itself as distinct from Wegovy.
Australians with type 2 diabetes represent the clearest and most affordable access pathway. With a valid PBS prescription from their GP or specialist, they pay the subsidised patient co-payment (~$42.50 general, ~$7.70 concession per month) and the government funds the remainder.
The prescribing process is straightforward. Your GP confirms the T2DM diagnosis, reviews your HbA1c results and prior medication history, rules out contraindications, and issues the PBS prescription. No specialist referral is required in most cases. The prescription is dispensed at any TGA-registered pharmacy carrying stock.
If you do not have type 2 diabetes but wish to access Ozempic for weight management, you can do so via a private prescription. Any Australian-registered medical practitioner — including GPs and telehealth doctors — can lawfully prescribe Ozempic off-label at their clinical discretion. The off-label pathway involves:
Telehealth access has made private Ozempic prescriptions more readily available, particularly for patients in regional areas. However, the monthly cost remains a significant barrier — which is precisely why the anticipated PBS listing for Wegovy (discussed below) is such a landmark development.
Ozempic is contraindicated in the following groups. Discuss with your healthcare provider if any of these apply to you:
Additional caution is warranted — and specialist input advisable — in people with a history of pancreatitis, significant renal impairment, or established diabetic retinopathy.
Ozempic and Wegovy both contain semaglutide — the same active molecule — but are distinct TGA-registered products with different doses, different approved indications, and critically different PBS access pathways:
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Maximum weekly dose | 2 mg | 2.4 mg |
| TGA indication | Type 2 diabetes | Chronic weight management |
| PBS listing (2026) | Yes — T2DM only | Under PBAC review for obesity |
| Private monthly cost | ~$120–$250 | ~$290–$400 |
| Primary trial programme | SUSTAIN series | STEP series |
The extra 0.4 mg per week separating Wegovy's 2.4 mg dose from Ozempic's maximum 2 mg is clinically meaningful. The STEP trials — the pivotal programme underpinning Wegovy's approval for obesity — used the 2.4 mg dose and delivered substantially greater weight loss than observed in the SUSTAIN T2DM trials at lower Ozempic doses:
The most consequential semaglutide access development in Australia in 2026 is the PBAC (Pharmaceutical Benefits Advisory Committee) review of Wegovy for PBS listing under the obesity indication. If approved, eligible patients — those with a BMI of 30 or above, or BMI 27+ with weight-related comorbidities such as hypertension, dyslipidaemia, or obstructive sleep apnoea — would access Wegovy at the PBS co-payment rate rather than full private cost.
This would represent the first PBS-subsidised GLP-1 medication for obesity in Australian history. For the complete breakdown of eligibility criteria, anticipated timelines, and practical implications, see the dedicated guide to the Wegovy PBS listing and access in Australia.
The practical decision framework: if you have type 2 diabetes, Ozempic on PBS is your most cost-effective semaglutide option. If you have obesity without T2DM and meet PBS criteria, Wegovy will likely be the appropriate subsidised route once fully listed. For a full Australian-focused comparison of semaglutide against tirzepatide — including PBS status, private costs, and clinical considerations — see the tirzepatide vs semaglutide Australia guide. Consult your GP or healthcare provider about which pathway applies to your situation.
The SUSTAIN trial series (SUSTAIN 1–10) evaluated semaglutide across a range of comparators in type 2 diabetes populations. Weight loss was consistently observed as a secondary outcome:
The STEP trials examined semaglutide 2.4 mg specifically in overweight and obese populations without the glycaemic control framing of SUSTAIN:
Published in 2023 and now embedded in prescribing rationale globally, the SELECT trial enrolled over 17,500 overweight or obese adults without diabetes who had established cardiovascular disease. Semaglutide 2.4 mg reduced the risk of MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% compared to placebo over a mean follow-up of 34 months.
This result is pivotal. It demonstrated cardioprotective benefit from semaglutide in people who had no diabetes indication, substantially strengthening the clinical case for PBS-subsidised access under an obesity indication and expanding the patient populations for whom GLP-1 therapy is clinically justified.
The most frequently reported adverse effects of Ozempic are gastrointestinal, concentrated in the first 2–4 weeks of each dose escalation step:
The standard clinical strategy is slow titration. Starting at 0.25 mg for four weeks before stepping up meaningfully reduces the severity and duration of these effects for most patients. Eating smaller meals, avoiding high-fat or spicy foods during titration, and maintaining good hydration are practical adjuncts. Discuss with your healthcare provider if side effects are persistent or severe.
A commonly raised concern is whether semaglutide causes disproportionate muscle loss alongside fat loss. The STEP-1 trial data on lean mass and semaglutide addresses this directly — lean mass loss during treatment is proportional to total weight lost, not greater than expected for the degree of weight reduction.
Pancreatitis: Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. Persistent severe abdominal pain, particularly if it radiates to the back, warrants immediate medical review. Ozempic should be discontinued and not restarted if pancreatitis is confirmed. People with a history of pancreatitis should discuss the risk-benefit balance carefully with their healthcare provider before initiating treatment.
Thyroid C-cell concerns: Rodent studies demonstrated dose-dependent thyroid C-cell tumours with semaglutide. This finding has not been replicated in humans across clinical trials or post-marketing surveillance to date, but it underpins the absolute contraindication in people with personal or family history of medullary thyroid carcinoma or MEN 2. Any new neck lump, persistent hoarseness, or difficulty swallowing should be reported to your GP promptly.
Diabetic retinopathy complications: In the SUSTAIN-6 trial, a higher early rate of retinopathy complications was observed in the semaglutide group — likely attributable to rapid glucose lowering in patients with pre-existing disease. People with established diabetic retinopathy should discuss this risk with their ophthalmologist or specialist before starting.
Hypoglycaemia: As monotherapy or with metformin, Ozempic carries very low hypoglycaemia risk. Risk increases meaningfully when combined with sulphonylureas or insulin — dose adjustments to those agents are often required on initiation.
Renal function: Nausea and vomiting sufficient to cause dehydration can impair kidney function, particularly in people with underlying chronic kidney disease. Adequate fluid intake during titration is important; specialist guidance is advisable for patients with significant renal impairment.
During the supply shortage, many Australians turned to compounding pharmacies as an alternative source of semaglutide. The TGA and the Australian Medical Association (AMA) have both issued clear public warnings about these products, and their position deserves direct attention.
Compounded semaglutide is prepared by licensed compounding pharmacists using bulk pharmaceutical ingredients. It is not the same as the TGA-registered Ozempic product. Key risks flagged by the TGA include:
With supply substantially stabilised in 2026, the supply rationale for compounded alternatives has largely dissolved. If you are currently using a compounded semaglutide product, consult your GP or healthcare provider about transitioning to the TGA-registered formulation.
Ozempic and Wegovy produce the most clinically significant pharmacological weight loss outside of bariatric surgery. But they are not appropriate for everyone, and even for those who do use them, lifestyle foundations meaningfully amplify outcomes. Evidence-based approaches explored across this site include:
Gut microbiome support: Research increasingly links microbiome composition to endogenous GLP-1 secretion from L-cells in the small intestine. Diets high in fermentable fibre and fermented foods appear to upregulate natural GLP-1 release. The gut microbiome and weight loss guide covers the mechanisms and practical dietary strategies.
Sleep optimisation: Chronic sleep deprivation elevates ghrelin (hunger hormone), suppresses leptin (satiety hormone), and impairs insulin sensitivity — all working directly against weight loss efforts. The sleep and weight loss connection covers what the research shows and actionable strategies.
Caloric deficit structure: Understanding your total daily energy expenditure and how to build a sustainable deficit is foundational to any weight management approach — including for people using GLP-1 medications, where managing intake intentionally amplifies outcomes. The caloric deficit guide covers TDEE calculation, safe rates of loss, metabolic adaptation, and protein-sparing strategies for Australians.
High-intensity interval training: HIIT improves insulin sensitivity, upregulates mitochondrial biogenesis, and produces favourable hormonal responses that support fat loss — including blunted compensatory hunger responses in some populations. The HIIT weight loss guide covers programming, evidence, and integration with dietary approaches.
The endogenous GLP-1 stimulus: A 2026 research finding from a Stanford-led group identified specific dietary patterns — high in resistant starches, polyphenols, and fermented foods — that appear to measurably stimulate endogenous GLP-1 secretion. The magnitude of this effect is substantially smaller than pharmacological GLP-1 agonism, but it supports dietary strategies as a credible adjunct for those on medication, or a standalone approach for those who are not. For a research-focused overview of how semaglutide sits alongside other peptide-based metabolic compounds — including AOD-9604 and Tesamorelin — the peptide weight loss stack comparison covers the mechanistic and regulatory distinctions in detail.
These approaches do not replicate the clinical efficacy of semaglutide for those requiring pharmacological intervention. But for the significant proportion of Australians who do not meet PBS criteria, cannot sustain private prescription costs, or prefer to avoid injection therapy, evidence-based lifestyle strategies represent a meaningful and accessible foundation.
Yes. Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) is TGA-registered and commercially available across Australia. Supply has substantially improved from the acute shortage conditions of 2023–2024, with reliable stock in most metropolitan pharmacies. Regional areas may still experience intermittent gaps — a courtesy call ahead to confirm availability before presenting a prescription remains advisable.
Cost depends on whether you access it via the PBS or a private prescription. For type 2 diabetes patients on PBS: approximately $42.50 per month (general patients) or $7.70 per month (concession card holders). For weight loss without T2DM on a private prescription: approximately $120–$170 per month at the 0.5 mg or 1 mg dose, or $200–$250 per month at 2 mg. Annual private prescription costs range from roughly $1,440 to $3,000 depending on dose.
Yes, but not on the PBS. Ozempic is PBS-listed only for type 2 diabetes. For weight loss without a T2DM diagnosis, you need a private prescription from a GP or telehealth doctor — at the full private cost of approximately $120–$250 per month depending on dose. The better-subsidised option for weight loss in Australia is Wegovy (semaglutide 2.4 mg), which is under PBAC review for PBS listing for obesity in 2026. Consult your GP about which product and pathway are appropriate for your individual circumstances.
Both contain semaglutide but differ in dose and approved indication. Ozempic is TGA-approved for type 2 diabetes at doses up to 2 mg weekly and is PBS-listed for that indication. Wegovy is TGA-approved specifically for chronic weight management in adults with obesity or overweight with comorbidities, at the higher dose of 2.4 mg weekly — which delivers greater average weight loss (~14–15% in STEP trials vs ~5–7% with Ozempic's T2DM doses). Wegovy is under review for PBS listing for obesity in 2026. Consult your healthcare provider about which product suits your situation.
Yes. Semaglutide's weight loss effects are not diabetes-dependent — they arise from GLP-1 receptor agonism in the hypothalamus and gut, which operates in all people regardless of glucose tolerance. The STEP 1 trial specifically enrolled people without diabetes and showed mean weight loss of 14.9% with semaglutide 2.4 mg over 68 weeks. The SELECT cardiovascular outcomes trial also enrolled non-diabetic participants and demonstrated a 20% reduction in MACE. The medication works; the question is which product, at which dose, is clinically appropriate — and whether PBS or private access applies to your situation. Always discuss with your healthcare provider.
The regulatory and access landscape for Ozempic in Australia continues to evolve rapidly. What began as a niche diabetes medication is now at the centre of mainstream obesity medicine, with PBS-subsidised access for weight management closer than it has ever been. Staying informed — and speaking with your healthcare provider — is the most direct path to making the right decision for your health.
Information current as of May 2026. TGA registration status and PBS listings are subject to change — verify current status via tga.gov.au and pbs.gov.au.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.